Metropolitan Dermatology Introduces Nevisense® Technology for Advanced Melanoma Detection
Now available in
Nevisense® utilizes electrical impedance spectroscopy (EIS) to analyze suspicious moles beneath the skin's surface, providing physicians with an additional layer of information beyond what can be seen visually. This advanced technology enhances clinical decision-making and supports earlier, more accurate detection of melanoma—the deadliest form of skin cancer.
"Early detection is critical when it comes to melanoma," said Dr.
Key Advantages of Nevisense® Include:
- Non-invasive and painless evaluation of suspicious lesions
- Improved diagnostic accuracy when used alongside visual examination and dermoscopy
- Reduction in unnecessary biopsies, helping patients avoid discomfort and scarring
- Early detection support, which is critical for successful melanoma treatment outcomes
Nevisense® is FDA-approved and widely used in
Patients visiting the
To learn more or to schedule an appointment, please contact
About Metropolitan Dermatology
Metropolitan Dermatology is a privately owned, leading provider of medical, surgical, and cosmetic dermatology services in New Jersey and Staten Island, New York. With a team of highly trained specialists and a commitment to innovation, the practice offers comprehensive care tailored to each patient's needs across multiple convenient locations.
Media Contact:
Kristine Walters
VP of Operations, Metropolitan Dermatology
732-574-1399, ext. 222
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/metropolitan-dermatology-introduces-nevisense-technology-for-advanced-melanoma-detection-302792655.html
SOURCE Metropolitan Dermatology
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Colt DCS appoints David Burton as Chief Information Officer
- Danske Bank share buy-back programme: transactions in week 27
- PROSUS N.V. ANNOUNCES CASH TENDER OFFERS FOR ANY AND ALL OF ITS 4.850% NOTES DUE 2027 AND FOR UP TO THE CAPPED MAXIMUM AMOUNT OF ITS 3.257% NOTES DUE 2027
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share